Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
37 "Lucia Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Reviews
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
J Pathol Transl Med. 2021;55(3):181-191.   Published online May 11, 2021
DOI: https://doi.org/10.4132/jptm.2021.03.23
  • 5,479 View
  • 294 Download
  • 10 Web of Science
  • 10 Crossref
AbstractAbstract PDF
Molecular biomarker testing is the standard of care for non–small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group co-published a molecular testing guideline which contained almost all known genetic changes that aid in treatment decisions or predict prognosis in patients with NSCLC. Since then there have been significant changes in targeted therapies as well as molecular testing including newly approved targeted drugs and liquid biopsy. In order to reflect these changes, the Korean Cardiopulmonary Pathology Study Group developed a consensus statement on molecular biomarker testing. This consensus statement was crafted to provide guidance on what genes should be tested, as well as methodology, samples, patient selection, reporting and quality control.

Citations

Citations to this article as recorded by  
  • Clinical utility of the Oncomine Dx Target Test multi‐CDx system and the possibility of utilizing those original sequence data
    Ayaka Saito, Hideki Terai, Tae‐Jung Kim, Katsura Emoto, Ryutaro Kawano, Kohei Nakamura, Hideyuki Hayashi, Hatsuyo Takaoka, Akihiko Ogata, Katsuhito Kinoshita, Fumimaro Ito, Lisa Shigematsu, Masahiko Okada, Takahiro Fukushima, Akifumi Mitsuishi, Taro Shino
    Cancer Medicine.2024;[Epub]     CrossRef
  • Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine
    Yurimi Lee, Boram Lee, Yoon-La Choi, Dong-Wook Kang, Joungho Han
    Modern Pathology.2024; : 100490.     CrossRef
  • FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC
    Anke Behnke, Anne Cayre, Giovanna De Maglio, Giuseppe Giannini, Lionel Habran, Marina Tarsitano, Massimiliano Chetta, David Cappellen, Alexandra Lespagnol, Cecile Le Naoures, Gabriella Massazza, Annarita Destro, Irina Bonzheim, Achim Rau, Achim Battmann,
    Pathology and Oncology Research.2023;[Epub]     CrossRef
  • Problems in the Pathologic Diagnosis of Suspected Lung Cancer
    Soo Han Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop Eom
    Tuberculosis and Respiratory Diseases.2023; 86(3): 176.     CrossRef
  • Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics
    Hyun Hee Koh, Eunhyang Park, Hyun-Soo Kim
    Diagnostics.2022; 12(2): 326.     CrossRef
  • Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics
    Yurimi Lee, Kiyong Na, Ha Young Woo, Hyun-Soo Kim
    Diagnostics.2022; 12(5): 1102.     CrossRef
  • Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
    Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2022; 56(5): 249.     CrossRef
  • Biomarker testing of cytology specimens in personalized medicine for lung cancer patients
    Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2022; 56(6): 326.     CrossRef
  • Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea
    Sunhee Chang, Yoon-La Choi, Hyo Sup Shim, Geon Kook Lee, Seung Yeon Ha
    Journal of Pathology and Translational Medicine.2022; 56(6): 334.     CrossRef
  • Lung Cancer in Korea
    Sehhoon Park, Chang-Min Choi, Seung-Sik Hwang, Yoon-La Choi, Hyae Young Kim, Young-Chul Kim, Young Tae Kim, Ho Yun Lee, Si Yeol Song, Myung-Ju Ahn
    Journal of Thoracic Oncology.2021; 16(12): 1988.     CrossRef
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
Dong Hoon Shin, Hyo Sup Shim, Tae Jung Kim, Heae Surng Park, Yun La Choi, Wan Seop Kim, Lucia Kim, Sun Hee Chang, Joon Seon Song, Hyo jin Kim, Jung Ho Han, Chang Hun Lee, Geon Kook Lee, Se Jin Jang
J Pathol Transl Med. 2019;53(3):153-158.   Published online February 28, 2019
DOI: https://doi.org/10.4132/jptm.2019.02.22
  • 7,163 View
  • 246 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDF
Liquid biopsy for detection of mutation from circulating tumor DNA is a new technology which is attractive in that it is non-invasive. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is an effective first line drug for advanced non-small cell lung cancer patients who harbor activating EGFR mutation. During the course of treatment, resistance against TKI arises which can be contributed to EGFR T790M mutation in about 50–60% of patients. Third generation TKI may overcome the resistance. In patients who cannot undergo tissue biopsy due to variable reasons, liquid biopsy is an excellent alternative for the detection of EGFR T790M mutation. However, this relatively novel method requires standardization and vigorous quality insurance. Thus, a standard set of guideline recommendations for liquid biopsy for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of provisional guideline recommendations that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

Citations

Citations to this article as recorded by  
  • Improving non-small-cell lung cancer survival through molecular characterization: Perspective of a multidisciplinary expert panel
    M.G.O. Fernandes, A.S. Vilariça, B. Fernandes, C. Camacho, C. Saraiva, F. Estevinho, H. Novais e Bastos, J.M. Lopes, P. Fidalgo, P. Garrido, S. Alves, S. Silva, T. Sequeira, F. Barata
    Pulmonology.2024; 30(1): 4.     CrossRef
  • Exosomes in Lung Cancer: Actors and Heralds of Tumor Development
    Amaia Sandúa, Estibaliz Alegre, Álvaro González
    Cancers.2021; 13(17): 4330.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • Current status and future perspectives of liquid biopsy in non-small cell lung cancer
    Sunhee Chang, Jae Young Hur, Yoon-La Choi, Chang Hun Lee, Wan Seop Kim
    Journal of Pathology and Translational Medicine.2020; 54(3): 204.     CrossRef
  • Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center
    Hazem Assi, Arafat Tfayli, Nada Assaf, Sarah Abou Daya, Aram H. Bidikian, Dima Kawsarani, Puzant Fermanian, Ghazi Zaatari, Rami Mahfouz
    Molecular Biology Reports.2019; 46(4): 3671.     CrossRef
Original Article
WITHDRAWN:A Clinicopathologic Study of 220 Cases of Pulmonary Sclerosing Pneumocytoma in Korea: A Nationwide Survey
Myunghee Kang, Seung Yeon Ha, Joung Ho Han, Mee Sook Roh, Se Jin Jang, Hee Jin Lee, Heae Surng Park, Geon Kook Lee, Kyo Young Lee, Jin-Haeng Chung, Yoo Duk Choi, Chang Hun Lee, Lucia Kim, Myoung Ja Chung, Soon Hee Jung, Gou Young Kim, Wan-Seop Kim
Received April 4, 2018  Accepted July 9, 2018  Published online July 16, 2018  
DOI: https://doi.org/10.4132/jptm.2018.07.10    [Accepted]
  • 4,865 View
  • 63 Download
Review
Molecular Testing of Lung Cancers
Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
J Pathol Transl Med. 2017;51(3):242-254.   Published online April 21, 2017
DOI: https://doi.org/10.4132/jptm.2017.04.10
  • 13,830 View
  • 579 Download
  • 24 Web of Science
  • 22 Crossref
AbstractAbstract PDF
Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories—mutations, gene rearrangements, and amplifications—and propose expanded guidelines on molecular testing of lung cancers.

Citations

Citations to this article as recorded by  
  • miR-92a-3p regulates cisplatin-induced cancer cell death
    Romain Larrue, Sandy Fellah, Nihad Boukrout, Corentin De Sousa, Julie Lemaire, Carolane Leboeuf, Marine Goujon, Michael Perrais, Bernard Mari, Christelle Cauffiez, Nicolas Pottier, Cynthia Van der Hauwaert
    Cell Death & Disease.2023;[Epub]     CrossRef
  • Molecular Pathology of Lung Cancer
    James J. Saller, Theresa A. Boyle
    Cold Spring Harbor Perspectives in Medicine.2022; 12(3): a037812.     CrossRef
  • Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
    Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2022; 56(5): 249.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis
    Kyungsoo Jung, Joon-Seok Choi, Beom-Mo Koo, Yu Jin Kim, Ji-Young Song, Minjung Sung, Eun Sol Chang, Ka-Won Noh, Sungbin An, Mi-Sook Lee, Kyoung Song, Hannah Lee, Ryong Nam Kim, Young Kee Shin, Doo-Yi Oh, Yoon-La Choi
    Cancer Research and Treatment.2021; 53(1): 9.     CrossRef
  • The promises and challenges of early non‐small cell lung cancer detection: patient perceptions, low‐dose CT screening, bronchoscopy and biomarkers
    Lukas Kalinke, Ricky Thakrar, Sam M. Janes
    Molecular Oncology.2021; 15(10): 2544.     CrossRef
  • Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review
    Anthony Yu, Eva Huang, Momoka Abe, Kang An, Sun-Kyeong Park, Chanhyun Park
    Expert Review of Pharmacoeconomics & Outcomes Research.2021; 21(3): 381.     CrossRef
  • The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC
    Parth Shah, Jacob Sands, Nicola Normanno
    Lung Cancer.2021; 160: 118.     CrossRef
  • Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
    Mercedes L Dalurzo, Alejandro Avilés-Salas, Fernando Augusto Soares, Yingyong Hou, Yuan Li, Anna Stroganova, Büge Öz, Arif Abdillah, Hui Wan, Yoon-La Choi
    OncoTargets and Therapy.2021; Volume 14: 4671.     CrossRef
  • Treatment of Patients With Non–Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations
    Melina E. Marmarelis, Corey J. Langer
    Clinical Lung Cancer.2020; 21(5): 395.     CrossRef
  • Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
    Eunhyang Park, Hyo Sup Shim
    Cancer Research and Treatment.2020; 52(2): 543.     CrossRef
  • High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma
    Yuyin Xu, Heng Chang, Lijing Wu, Xin Zhang, Ling Zhang, Jing Zhang, Yuan Li, Lei Shen, Xiaoli Zhu, Xiaoyan Zhou, Qianming Bai
    Experimental and Molecular Pathology.2020; 117: 104548.     CrossRef
  • An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients
    Jiacong Wei, Anna A. Rybczynska, Pei Meng, Martijn Terpstra, Ali Saber, Jantine Sietzema, Wim Timens, Ed Schuuring, T. Jeroen N. Hiltermann, Harry. J.M. Groen, Anthonie van der Wekken, Anke van den Berg, Klaas Kok
    Cancers.2020; 12(10): 2843.     CrossRef
  • Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
    Alexander Gavralidis, Justin F. Gainor
    The Cancer Journal.2020; 26(6): 517.     CrossRef
  • Role of Immunocytochemistry in the Cytological Diagnosis of Pulmonary Tumors
    Jasna Metovic, Luisella Righi, Luisa Delsedime, Marco Volante, Mauro Papotti
    Acta Cytologica.2020; 64(1-2): 16.     CrossRef
  • Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer
    Eun Kyung Kim, Kyung A. Kim, Chang Young Lee, Sangwoo Kim, Sunhee Chang, Byoung Chul Cho, Hyo Sup Shim
    Clinical Lung Cancer.2019; 20(1): e123.     CrossRef
  • PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
    Jongmin Lee, Chan Kwon Park, Hyoung‐Kyu Yoon, Young Jo Sa, In Sook Woo, Hyo Rim Kim, Sue Youn Kim, Tae‐Jung Kim
    Thoracic Cancer.2019; 10(1): 103.     CrossRef
  • Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
    Yeon Bi Han, Hyun Jung Kwon, Soo Young Park, Eun-Sun Kim, Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2019; 53(2): 86.     CrossRef
  • Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
    Pathmanathan Rajadurai, Phaik Leng Cheah, Soon Hin How, Chong Kin Liam, Muhammad Azrif Ahmad Annuar, Norhayati Omar, Noriah Othman, Nurhayati Mohd Marzuki, Yong Kek Pang, Ros Suzanna Ahmad Bustamam, Lye Mun Tho
    Lung Cancer.2019; 136: 65.     CrossRef
  • Somatic mutations and immune checkpoint biomarkers
    Brielle A. Parris, Eloise Shaw, Brendan Pang, Richie Soong, Kwun Fong, Ross A. Soo
    Respirology.2019; 24(3): 215.     CrossRef
  • Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib
    Anna Chalmers, Laura Cannon, Wallace Akerley
    The Oncologist.2019; 24(7): 963.     CrossRef
  • Genetic and clinicopathologic characteristics of lung adenocarcinoma with tumor spread through air spaces
    Jae Seok Lee, Eun Kyung Kim, Moonsik Kim, Hyo Sup Shim
    Lung Cancer.2018; 123: 121.     CrossRef
Original Articles
Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma
Chang Hwan Choi, Young Hoon Park, Joo Han Lim, Suk Jin Choi, Lucia Kim, In Suh Park, Jee Young Han, Joon Mee Kim, Young Chae Chu
J Pathol Transl Med. 2016;50(2):96-103.   Published online February 15, 2016
DOI: https://doi.org/10.4132/jptm.2016.01.12
  • 8,708 View
  • 108 Download
  • 11 Web of Science
  • 12 Crossref
AbstractAbstract PDF
Background
Immunohistochemical demonstration of CD20 in diffuse large B-cell lymphoma (DLBCL) is prerequisite not only for the diagnosis but also for assigning patients to rituximab-containing chemotherapy. However, little is known about the impact of abundance of CD20 expression assessed by immunohistochemistry on the clinical outcome of DLBCL. We performed a semi-quantitative immunohistochemical analysis of CD20 expression in DLBCL to examine the prognostic implication of the level of CD20 expression. Methods: Pre-treatment diagnostic tissue samples from 48 DLBCL patients who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen were represented in a tissue microarray and immunostained for CD20. The relative abundance of CD20 expression was semi-quantitatively scored using a web-based ImmunoMembrane plug-in. Receiver operating characteristic curve analysis was used to determine a prognostically relevant cut-off score in order to dichotomize the patients into CD20-high versus CD20-low groups. Results: The levels of CD20 expression were heterogeneous among the patients, with a wide and linear distribution of scores. Patients in CD20-low group showed significantly poor clinical outcome. Conclusions: The levels of CD20 expression in DLBCL are heterogeneous among the patients with DLBCL. A subgroup of the patients with CD20 expression levels below the cut-off score showed poor clinical outcome.

Citations

Citations to this article as recorded by  
  • The Expression Levels of CD20 as a Prognostic Value in Feline B-Cell Nasal Lymphoma: A Pilot Study
    Kravee Chaipoca, Theerapol Sirinarumitr, Supreeya Srisampan, Charuwan Wongsali, Attawit Kovitvadhi, Tassanee Jaroensong
    Animals.2024; 14(7): 1043.     CrossRef
  • Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
    Sotirios G. Papageorgiou, Thomas P. Thomopoulos, Ioannis Katagas, Anthi Bouchla, Vassiliki Pappa
    Therapeutic Advances in Hematology.2021; 12: 204062072110139.     CrossRef
  • Novel tumour–infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma
    Qiqi Zhu, Xueqin Deng, Wenqing Yao, Zihang Chen, Yunxia Ye, Limin Gao, Wenyan Zhang, Weiping Liu, Sha Zhao
    Annals of Hematology.2021; 100(3): 715.     CrossRef
  • Induced CD20 Expression on B-Cell Malignant Cells Heightened the Cytotoxic Activity of Chimeric Antigen Receptor Engineered T Cells
    Yingxi Xu, Saisai Li, Ying Wang, Jia Liu, Xinhe Mao, Haiyan Xing, Zheng Tian, Kejing Tang, Xiaolong Liao, Qing Rao, Dongsheng Xiong, Min Wang, Jianxiang Wang
    Human Gene Therapy.2019; 30(4): 497.     CrossRef
  • Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity
    Hyang Joo Ryu, Eun Kyung Kim, Byoung Chul Cho, Sun Och Yoon
    Head & Neck.2019; 41(1): 198.     CrossRef
  • Immunoglobulin D (IgD) and IgD receptor expression in diffuse large B-cell lymphoma
    Xing Dai, Yu-Jing Wu, Xiao-Yi Jia, Yan Chang, Hua-Xun Wu, Chun Wang, Wei Wei
    Hematology.2019; 24(1): 544.     CrossRef
  • The implications of TrkA and MET aberrations in de novo salivary duct carcinoma
    Hyang Joo Ryu, Yoon Woo Koh, Sun Och Yoon
    Human Pathology.2018; 81: 18.     CrossRef
  • Prognostic stratification improvement by integrating ID1/ID3/IGJ gene expression signature and immunophenotypic profile in adult patients with B-ALL
    Nataly Cruz-Rodriguez, Alba L. Combita, Leonardo J. Enciso, Lauren F. Raney, Paula L. Pinzon, Olga C. Lozano, Alba M. Campos, Niyireth Peñaloza, Julio Solano, Maria V. Herrera, Jovanny Zabaleta, Sandra Quijano
    Journal of Experimental & Clinical Cancer Research.2017;[Epub]     CrossRef
  • Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma
    Juhyeon Jeong, Eun Ji Oh, Woo Ick Yang, Soo Jeong Kim, Sun Och Yoon
    Human Pathology.2017; 64: 222.     CrossRef
  • Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma
    Hyang Joo Ryu, Eun Kyung Kim, Su Jin Heo, Byoung Chul Cho, Hye Ryun Kim, Sun Och Yoon
    APMIS.2017; 125(11): 974.     CrossRef
  • New developments in the pathology of malignant lymphoma. A review of the literature published from January–April 2016
    J. Han van Krieken
    Journal of Hematopathology.2016; 9(2): 73.     CrossRef
  • Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
    Bertrand Coiffier, Clémentine Sarkozy
    Hematology.2016; 2016(1): 366.     CrossRef
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Sang Hwa Lee, Wan Seop Kim, Yoo Duk Choi, Jeong Wook Seo, Joung Ho Han, Mi Jin Kim, Lucia Kim, Geon Kook Lee, Chang Hun Lee, Mee Hye Oh, Gou Young Kim, Sun Hee Sung, Kyo Young Lee, Sun Hee Chang, Mee Sook Rho, Han Kyeom Kim, Soon Hee Jung, Se Jin Jang, The Cardiopulmonary Pathology Study Group of Korean Society of Pathologists
J Pathol Transl Med. 2015;49(6):481-488.   Published online October 13, 2015
DOI: https://doi.org/10.4132/jptm.2015.09.14
  • 10,288 View
  • 94 Download
  • 19 Web of Science
  • 21 Crossref
AbstractAbstract PDF
Background
Analysis of mutations in the epidermal growth factor receptor gene (EGFR) is important for predicting response to EGFR tyrosine kinase inhibitors. The overall rate of EGFR mutations in Korean patients is variable. To obtain comprehensive data on the status of EGFR mutations in Korean patients with lung cancer, the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists initiated a nationwide survey. Methods: We obtained 1,753 reports on EGFR mutations in patients with lung cancer from 15 hospitals between January and December 2009. We compared EGFR mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status. Results: The overall EGFR mutation rate was 34.3% in patients with non-small cell lung cancer (NSCLC) and 43.3% in patients with adenocarcinoma. EGFR mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy. EGFR mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC. Conclusions: EGFR mutation rates and statuses were similar to those in published data from other East Asian countries.

Citations

Citations to this article as recorded by  
  • The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia
    Noni Novisari Soeroso, Fannie Rizki Ananda, Johan Samuel Sitanggang, Noverita Sprinse Vinolina
    F1000Research.2023; 11: 853.     CrossRef
  • Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients
    Changlong He, Chengcheng Wei, Jun Wen, Shi Chen, Ling Chen, Yue Wu, Yifan Shen, Huili Bai, Yangli Zhang, Xueping Chen, Xiaosong Li
    Journal of Cancer Research and Clinical Oncology.2022; 148(2): 321.     CrossRef
  • Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China
    Jun-Ling Wang, Yu-Dong Fu, Yan-Hong Gao, Xiu-Ping Li, Qian Xiong, Rui Li, Bo Hou, Ruo-Shan Huang, Jun-Feng Wang, Jian-Kun Zhang, Jia-Ling Lv, Chao Zhang, Hong-Wei Li
    Genes and Environment.2022;[Epub]     CrossRef
  • Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
    Min Yu, Xiaoyu Li, Xueqian Wu, Weiya Wang, Yanying Li, Yan Zhang, Shuang Zhang, Yongsheng Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia
    Noni Novisari Soeroso, Fannie Rizki Ananda, Johan Samuel Sitanggang, Noverita Sprinse Vinolina
    F1000Research.2022; 11: 853.     CrossRef
  • Adverse Event Profiles of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Adenocarcinoma Lung Patients in North Sumatera Population
    Moh. Ramadhani Soeroso, Noni Novisari Soeroso, Setia Putra Tarigan, Elisna Syahruddin
    Open Access Macedonian Journal of Medical Sciences.2022; 10(T7): 134.     CrossRef
  • Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
    Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2022; 56(5): 249.     CrossRef
  • Traditional Chinese Medicine Syndromes are Associated with Driver Gene Mutations and Clinical Characteristics in Patients with Lung Adenocarcinoma
    Jili Yang, Haiyan Lu, Niancai Jing, Bo Wang, Huanyu Guo, Shoukun Sun, Yue Zhang, Chan-Yen Kuo
    Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1.     CrossRef
  • Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy
    Yoonjung Kim, Saeam Shin, Kyung-A Lee
    Cancer Cell International.2021;[Epub]     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
    Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee
    Cancer Research and Treatment.2020; 52(1): 284.     CrossRef
  • Long non-coding RNA ATB promotes human non-small cell lung cancer proliferation and metastasis by suppressing miR-141-3p
    Guojie Lu, Yaosen Zhang, Klaus Roemer
    PLOS ONE.2020; 15(2): e0229118.     CrossRef
  • Prognostic Role of S100A8 and S100A9 Protein Expressions in Non-small Cell Carcinoma of the Lung
    Hyun Min Koh, Hyo Jung An, Gyung Hyuck Ko, Jeong Hee Lee, Jong Sil Lee, Dong Chul Kim, Jung Wook Yang, Min Hye Kim, Sung Hwan Kim, Kyung Nyeo Jeon, Gyeong-Won Lee, Se Min Jang, Dae Hyun Song
    Journal of Pathology and Translational Medicine.2019; 53(1): 13.     CrossRef
  • Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
    Yongchun Zhou, Yuhui Ma, Hutao Shi, Yaxi Du, Yunchao Huang
    Scientific Reports.2018;[Epub]     CrossRef
  • Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
    Yong Won Choi, Jin-Hyuk Choi
    The Korean Journal of Internal Medicine.2017; 32(3): 422.     CrossRef
  • Molecular Testing of Lung Cancers
    Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
    Journal of Pathology and Translational Medicine.2017; 51(3): 242.     CrossRef
  • MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
    Geun Dong Lee, Seung Eun Lee, Doo-Yi Oh, Dan-bi Yu, Hae Min Jeong, Jooseok Kim, Sungyoul Hong, Hun Soon Jung, Ensel Oh, Ji-Young Song, Mi-Sook Lee, Mingi Kim, Kyungsoo Jung, Jhingook Kim, Young Kee Shin, Yoon-La Choi, Hyeong Ryul Kim
    Journal of Thoracic Oncology.2017; 12(8): 1233.     CrossRef
  • Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
    Yongchun Zhou, Yanlong Yang, Chenggang Yang, Yunlan Chen, Changshao Yang, Yaxi Du, Guangqiang Zhao, Yinjin Guo, Lianhua Ye, Yunchao Huang
    Oncotarget.2017; 8(9): 15023.     CrossRef
  • Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer
    Seung Eun Lee, So-Young Lee, Hyung-Kyu Park, Seo-Young Oh, Hee-Joung Kim, Kye-Young Lee, Wan-Seop Kim
    Journal of Korean Medical Science.2016; 31(8): 1224.     CrossRef
  • MassARRAY, pyrosequencing, and PNA clamping for EGFR mutation detection in lung cancer tissue and cytological samples: a multicenter study
    Kyueng-Whan Min, Wan-Seop Kim, Se Jin Jang, Yoo Duk Choi, Sunhee Chang, Soon Hee Jung, Lucia Kim, Mee-Sook Roh, Choong Sik Lee, Jung Weon Shim, Mi Jin Kim, Geon Kook Lee
    Journal of Cancer Research and Clinical Oncology.2016; 142(10): 2209.     CrossRef
  • Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
    Boram Lee, Taebum Lee, Se-Hoon Lee, Yoon-La Choi, Joungho Han
    Oncotarget.2016; 7(17): 23874.     CrossRef
Brief Case Report
Myoepithelial Carcinoma of Soft Tissue: A Case Report and Review of the Literature
Chang Hwan Choi, Young Chae Chu, Lucia Kim, Suk Jin Choi, In Suh Park, Jee Young Han, Joon Mee Kim
Korean J Pathol. 2014;48(6):413-417.   Published online December 31, 2014
DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.6.413
  • 10,473 View
  • 114 Download
  • 6 Crossref
PDF

Citations

Citations to this article as recorded by  
  • EWSR1::NR4A3 gene fusion in a cutaneous atypical myoepithelial neoplasm
    Ashley Rose Scholl, Evelyna Kliassov, Diana M. Cardona, Rex Bentley, Rami N. Al‐Rohil
    Journal of Cutaneous Pathology.2023; 50(7): 601.     CrossRef
  • Abdominal myoepithelial carcinoma: A rare abdominal wall entity of an uncommon tumor
    Daania Shoaib, Saqib Raza Khan, Yasmin Abdul Rashid, Muhammad Nauman Zahir
    International Journal of Surgery Case Reports.2022; 99: 107618.     CrossRef
  • Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy
    Florence Chamberlain, Elena Cojocaru, Mariana Scaranti, Jonathan Noujaim, Anastasia Constantinou, Khin Thway, Cyril Fisher, Christina Messiou, Dirk C. Strauss, Aisha Miah, Shane Zaidi, Charlotte Benson, Spyridon Gennatas, Robin L. Jones
    Medical Oncology.2020;[Epub]     CrossRef
  • Foot plantar soft tissue malignant myoepithelioma tumor: Case report and review of the literature
    Manuel Trevino, Chetan Moorthy, Lisa Kafchinski, Daniel Bustamante
    Clinical Imaging.2020; 61: 90.     CrossRef
  • Presumed choroidal metastasis from soft tissue myoepithelial carcinoma
    Michelle M. Hui, Rohan Merani, Fiona Bonar, Angela M. Hong, Adrian T. Fung
    American Journal of Ophthalmology Case Reports.2019; 14: 55.     CrossRef
  • Myoepithelial carcinoma of the elbow diagnosed by immunohistochemistry: Case report of an uncommon neoplasm with metastatic recurrence
    Madhura Mahapatra, Travis Lambert, Abdal Rahman El-Mallah, Andressa Balbi, Mohamad Aziz
    Case Reports International.2019; 8(2): 1.     CrossRef
Original Articles
Preparation of Compact Agarose Cell Blocks from the Residues of Liquid-Based Cytology Samples
Suk Jin Choi, Yeon Il Choi, Lucia Kim, In Suh Park, Jee Young Han, Joon Mee Kim, Young Chae Chu
Korean J Pathol. 2014;48(5):351-360.   Published online October 27, 2014
DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.5.351
  • 13,128 View
  • 294 Download
  • 19 Crossref
AbstractAbstract PDF
Background: Inevitable loss of diagnostic material should be minimized during cell block preparation. We introduce a modified agarose cell block technique that enables the synthesis of compact cell blocks by using the entirety of a cell pellet without the loss of diagnostic material during cell block preparations. The feasibility of this technique is illustrated by high-throughput immunocytochemistry using high-density cell block microarray (CMA). Methods: The cell pellets of Sure- Path residues were pre-embedded in ultra-low gelling temperature agarose gel and re-embedded in standard agarose gel. They were fixed, processed, and embedded in paraffin using the same method as tissue sample processing. The resulting agarose cell blocks were trimmed and represented on a CMA for high-throughput analysis using immunocytochemical staining. Results: The SurePath residues were effectively and entirely incorporated into compact agarose cell buttons and embedded in paraffin. Sections of the agarose cell blocks revealed cellularities that correlated well with corresponding SurePath smears and had immunocytochemical features that were sufficient for diagnosis of difficult cases. Conclusions: This agarose-based compact cell block technique enables preparation of high-quality cell blocks by using up the residual SurePath samples without loss of diagnostic material during cell block preparation.

Citations

Citations to this article as recorded by  
  • Immunocytochemistry on frozen-embedded cell block for the diagnosis of hematolymphoid cytology specimen: a straightforward alternative to the conventional cell block
    Youjeong Seo, Sanzida Alam Prome, Lucia Kim, Jee Young Han, Joon Mee Kim, Suk Jin Choi
    Journal of Hematopathology.2024; 17(1): 1.     CrossRef
  • Comparison of liquid-based cytology and cell blocks prepared from cell remnants for diagnosis of cervical pathology
    Elif Kuzucular, Ferhat Ozden, Bahar Muezzinoglu
    Annals of Diagnostic Pathology.2024; 69: 152265.     CrossRef
  • Cell blocks in cytology: review of preparation methods, advantages, and limitations
    Vanda F. Torous, Jacqueline M. Cuda, Varsha Manucha, Melissa L. Randolph, Qiuying Shi, Christopher J. VandenBussche
    Journal of the American Society of Cytopathology.2023; 12(2): 77.     CrossRef
  • Cerebral Organoid Arrays for Batch Phenotypic Analysis in Sections and Three Dimensions
    Juan Chen, Haihua Ma, Zhiyu Deng, Qingming Luo, Hui Gong, Ben Long, Xiangning Li
    International Journal of Molecular Sciences.2023; 24(18): 13903.     CrossRef
  • Diagnosis of pancreatic solid pseudopapillary neoplasms using cell‐blocks and immunohistochemical evaluation of endoscopic ultrasound‐guided fine needle aspiration biopsy specimens
    José Celso Ardengh, César Vivian Lopes, Filadélfio Euclides Venco, Marcel Autran Machado
    Cytopathology.2021; 32(1): 50.     CrossRef
  • Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy
    Matt Lechner, Volker H. Schartinger, Christopher D. Steele, Wen Long Nei, Marc Lucas Ooft, Liesa-Marie Schreiber, Christodoulos P. Pipinikas, Grace Tin-Yun Chung, Yuk Yu Chan, Feng Wu, Ka-Fai To, Chi Man Tsang, Wayne Pearce, Daniele Morelli, Martin Philpo
    Nature Communications.2021;[Epub]     CrossRef
  • Utility of PD‐L1 immunocytochemistry using body‐fluid cell blocks in patients with non‐small‐cell lung cancer
    Seung Geun Song, Jonghoon Lee, Jaemoon Koh, Sehui Kim, Doo Hyun Chung, Yoon Kyung Jeon
    Diagnostic Cytopathology.2020; 48(4): 291.     CrossRef
  • Agarose cell block and ancillary molecular tests enhance diagnostic efficacy of liquid-based cytology samples
    EmanS Abusinna, MervatM El-Deftar, YasmineF El-Esawy
    Egyptian Journal of Pathology.2020; 40(2): 169.     CrossRef
  • Brain-Derived Neurotrophin and TrkB in Head and Neck Squamous Cell Carcinoma
    József Dudás, Anna Riml, Raphaela Tuertscher, Christian Pritz, Teresa Steinbichler, Volker Schartinger, Susanne Sprung, Rudolf Glueckert, Anneliese Schrott-Fischer, Lejo Johnson Chacko, Herbert Riechelmann
    International Journal of Molecular Sciences.2019; 20(2): 272.     CrossRef
  • Pleiotropic Effects of Epithelial Mesenchymal Crosstalk on Head and Neck Cancer: EMT and beyond
    T. B. Steinbichler, D. Savic, D. Dejaco, A. Romani, B. Kofler, I. I. Skvortsova, H. Riechelmann, J. Dudas
    Cancer Microenvironment.2019; 12(2-3): 67.     CrossRef
  • Microarray Embedding/Sectioning for Parallel Analysis of 3D Cell Spheroids
    Jonathan Gabriel, David Brennan, Jennifer H. Elisseeff, Vince Beachley
    Scientific Reports.2019;[Epub]     CrossRef
  • Photodynamic Effect of Methylene Blue and Low Level Laser Radiation in Head and Neck Squamous Cell Carcinoma Cell Lines
    Barbara Kofler, Angela Romani, Christian Pritz, Teresa Steinbichler, Volker Schartinger, Herbert Riechelmann, Jozsef Dudas
    International Journal of Molecular Sciences.2018; 19(4): 1107.     CrossRef
  • Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme
    Chia-Ing Jan, Wan-Chen Tsai, Horng-Jyh Harn, Woei-Cherng Shyu, Ming-Chao Liu, Hsin-Man Lu, Shao-Chih Chiu, Der-Yang Cho
    Frontiers in Immunology.2018;[Epub]     CrossRef
  • Nerve Growth Factor (NGF)—Receptor Survival Axis in Head and Neck Squamous Cell Carcinoma
    József Dudás, Wolfgang Dietl, Angela Romani, Susanne Reinold, Rudolf Glueckert, Anneliese Schrott-Fischer, Daniel Dejaco, Lejo Johnson Chacko, Raphaela Tuertscher, Volker Schartinger, Herbert Riechelmann
    International Journal of Molecular Sciences.2018; 19(6): 1771.     CrossRef
  • Cell blocks in cytopathology: An update
    Aruna Nambirajan, Deepali Jain
    Cytopathology.2018; 29(6): 505.     CrossRef
  • Cell transfer technique for constructing cytological microarrays for immunocytochemical analysis
    C.‐H. Wen, C.‐H. Lin, P.‐L. Ko, Y.‐F. Kuo, Y.‐J. Chen, C.‐Y. Chai
    Cytopathology.2017; 28(2): 157.     CrossRef
  • Cell and Tissue Display
    Nicholas Theodosakis, Goran Micevic, Marcus W. Bosenberg, Nemanja Rodić
    Journal of Histochemistry & Cytochemistry.2016; 64(7): 403.     CrossRef
  • Diagnostic Usefulness of Claudin-3 and Claudin-4 for Immunocytochemical Differentiation between Metastatic Adenocarcinoma Cells and Reactive Mesothelial Cells in Effusion Cell Blocks
    Nah Ihm Kim, Ga-Eon Kim, Ji Shin Lee
    Acta Cytologica.2016; 60(3): 232.     CrossRef
  • Do We Know What Is in Our Samples?
    Louise Gilroy, Kathy Walsh, Anca Oniscu
    Journal of Thoracic Oncology.2015; 10(12): e122.     CrossRef
The Clinicopathological Significance of Epithelial Mesenchymal Transition Associated Protein Expression in Head and Neck Squamous Cell Carcinoma
Kyu Ho Kim, Lucia Kim, Suk Jin Choi, Jee Young Han, Joon Mee Kim, Young Chae Chu, Young-Mo Kim, In Suh Park, Joo Han Lim
Korean J Pathol. 2014;48(4):263-269.   Published online August 26, 2014
DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.4.263
  • 7,316 View
  • 50 Download
  • 11 Crossref
AbstractAbstract PDF
Background

Epithelial mesenchymal transition (EMT) has an important role in invasion and metastasis of tumor cells. The purpose of this study was to evaluate the roles of EMT-associated proteins on progression and metastasis as a prognostic/predictive factor in curatively-resected (R0) head and neck squamous cell carcinoma (HNSCC).

Methods

A total of 118 patients who received curative surgery for HNSCC at Inha University Hospital between January 1996 and December 2011 were included. We used protein immunohistochemistry to evaluate the expression of E-cadherin, vimentin, and EZH2 on tissue microarrays. Also, we reviewed all medical records and analyzed the relationship between the expression of EMT-associated proteins and prognosis.

Results

The E-cadherin-negative group showed more moderate/poor differentiation of cancer cell type than the higher E-cadherin-expressing group (p=.016) and high EZH2 expression was significantly correlated with nodal metastasis (p=.012). Our results demonstrate a significant association between high expression of EZH2 and vimentin and presence of distant progression (p=.026). However, expression of E-cadherin, vimentin, and EZH2 was not significantly associated with overall survival.

Conclusions

These findings suggest that an EMT-associated protein expression profile is correlated with aggressiveness of disease and prognosis, and could be a useful marker for determination of additional treatment in curatively-resected HNSCC patients.

Citations

Citations to this article as recorded by  
  • Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma
    Yuxi Cheng, Zhengzheng Song, Xiaodan Fang, Zhangui Tang
    Clinical Epigenetics.2024;[Epub]     CrossRef
  • Prognostic Value of TWIST1 and EZH2 Expression in Colon Cancer
    Samar M. Abdel Raouf, Taiseer R. Ibrahim, Lobna A. Abdelaziz, Mohamed I. Farid, Salem Y Mohamed
    Journal of Gastrointestinal Cancer.2021; 52(1): 90.     CrossRef
  • HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis
    Kyungmin Lee, Jae Won Chang, Chan Oh, Lihua Liu, Seung-Nam Jung, Ho-Ryun Won, Young Il Kim, Ki-Sang Rha, Bon Seok Koo
    European Journal of Surgical Oncology.2020; 46(6): 1066.     CrossRef
  • EZH2 overexpression in head and neck cancer is related to lymph node metastasis
    Julie C. Nienstedt, Cornelia Schroeder, Till Clauditz, Ronald Simon, Guido Sauter, Adrian Muenscher, Marco Blessmann, Henning Hanken, Christina Pflug
    Journal of Oral Pathology & Medicine.2018; 47(3): 240.     CrossRef
  • MiR-876-5p modulates head and neck squamous cell carcinoma metastasis and invasion by targeting vimentin
    Yibo Dong, Yang Zheng, Chundi Wang, Xu Ding, Yifei Du, Laikui Liu, Wei Zhang, Wei Zhang, Yi Zhong, Yunong Wu, Xiaomeng Song
    Cancer Cell International.2018;[Epub]     CrossRef
  • HMGA2 is associated with the aggressiveness of tongue squamous cell carcinoma
    H Zhang, Z Tang, C Deng, Y He, F Wu, O Liu, C Hu
    Oral Diseases.2017; 23(2): 255.     CrossRef
  • miR-375 Regulates Invasion-Related Proteins Vimentin and L-Plastin
    Lizandra Jimenez, Jihyeon Lim, Berta Burd, Thomas M. Harris, Thomas J. Ow, Nicole Kawachi, Thomas J. Belbin, Ruth Angeletti, Michael B. Prystowsky, Geoffrey Childs, Jeffrey E. Segall
    The American Journal of Pathology.2017; 187(7): 1523.     CrossRef
  • Functional and therapeutic significance of EZH2 in urological cancers
    Xiaobing Liu, Qingjian Wu, Longkun Li
    Oncotarget.2017; 8(23): 38044.     CrossRef
  • EZH2, an on–off valve in signal network of tumor cells
    Shanshan Sun, Feng Yu, Lun Zhang, Xuan Zhou
    Cellular Signalling.2016; 28(5): 481.     CrossRef
  • High EZH2 Protein Expression Is Associated with Poor Overall Survival in Patients with Luminal A Breast Cancer
    Si-Hyong Jang, Jong Eun Lee, Mee-Hye Oh, Ji-Hye Lee, Hyun Deuk Cho, Kyung-Ju Kim, Sung Yong Kim, Sun Wook Han, Han Jo Kim, Sang Byung Bae, Hyun Ju Lee
    Journal of Breast Cancer.2016; 19(1): 53.     CrossRef
  • EZH2 promotes invasion and metastasis of laryngeal squamous cells carcinoma via epithelial-mesenchymal transition through H3K27me3
    HuaNan Luo, Yuan Jiang, SiJing Ma, HuanHuan Chang, ChunXi Yi, Hui Cao, Ying Gao, HaiLi Guo, Jin Hou, Jing Yan, Ying Sheng, XiaoYong Ren
    Biochemical and Biophysical Research Communications.2016; 479(2): 253.     CrossRef
Review
Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group
Hyojin Kim, Hyo Sup Shim, Lucia Kim, Tae-Jung Kim, Kun Young Kwon, Geon Kook Lee, Jin-Haeng Chung
Korean J Pathol. 2014;48(1):1-9.   Published online February 25, 2014
DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.1.1
  • 12,321 View
  • 113 Download
  • 19 Crossref
AbstractAbstract PDF

Rearrangement of anaplastic lymphoma kinase (ALK) gene is the best predictor of response to crizotinib, an ALK tyrosine kinase inhibitor. However, the prevalence of the ALK fusion is low, so accurate patient identification is crucial for successful treatment using ALK inhibitors. Furthermore, most patients with lung cancer present with advanced-stage disease at the time of diagnosis, so it is important for pathologists to detect ALK-rearranged patients while effectively maximizing small biopsy or cytology specimens. In this review, we propose a guideline recommendation for ALK testing approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

Citations

Citations to this article as recorded by  
  • Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
    Gabriele Gamerith, Marcel Kloppenburg, Finn Mildner, Arno Amann, Sabine Merkelbach-Bruse, Carina Heydt, Janna Siemanowski, Reinhard Buettner, Michael Fiegl, Claudia Manzl, Georg Pall
    Cancers.2022; 14(20): 5113.     CrossRef
  • ALK Translocation in ALK-Positive Mesenchymal Tumors: Diagnostic and Therapeutic Insights
    Minsun Jung, Kyung Chul Moon, Jeongmo Bae, Tae Min Kim, Miso Kim, Yoon Kyung Jeon, Cheol Lee
    Archives of Pathology & Laboratory Medicine.2022; 146(12): 1460.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
    Mercedes L Dalurzo, Alejandro Avilés-Salas, Fernando Augusto Soares, Yingyong Hou, Yuan Li, Anna Stroganova, Büge Öz, Arif Abdillah, Hui Wan, Yoon-La Choi
    OncoTargets and Therapy.2021; Volume 14: 4671.     CrossRef
  • Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
    Pathmanathan Rajadurai, Phaik Leng Cheah, Soon Hin How, Chong Kin Liam, Muhammad Azrif Ahmad Annuar, Norhayati Omar, Noriah Othman, Nurhayati Mohd Marzuki, Yong Kek Pang, Ros Suzanna Ahmad Bustamam, Lye Mun Tho
    Lung Cancer.2019; 136: 65.     CrossRef
  • Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
    Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley, Eric H. Bernicker, Carol Colasacco, Sanja Dacic, Fred R. Hirsch, Keith Kerr, David J. Kwiatkowski, Marc Ladanyi, Jan A. Nowak, Lynette Sholl, Robyn Temple-Smolkin, Benj
    Journal of Thoracic Oncology.2018; 13(3): 323.     CrossRef
  • Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
    Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley, Eric H. Bernicker, Carol Colasacco, Sanja Dacic, Fred R. Hirsch, Keith Kerr, David J. Kwiatkowski, Marc Ladanyi, Jan A. Nowak, Lynette Sholl, Robyn Temple-Smolkin, Benj
    The Journal of Molecular Diagnostics.2018; 20(2): 129.     CrossRef
  • Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the
    Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley, Eric H Bernicker, Carol Colasacco, Sanja Dacic, Fred R. Hirsch, Keith Kerr, David J. Kwiatkowski, Marc Ladanyi, Jan A. Nowak, Lynette Sholl, Robyn Temple-Smolkin, Benja
    Archives of Pathology & Laboratory Medicine.2018; 142(3): 321.     CrossRef
  • 5′/ 3′ imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer
    Yongqing Tong, Zhijun Zhao, Bei Liu, Anyu Bao, Hongyun Zheng, Jian Gu, Mary McGrath, Ying Xia, Bihua Tan, Chunhua Song, Yan Li
    Journal of Experimental & Clinical Cancer Research.2018;[Epub]     CrossRef
  • Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study
    Dae Ho Lee, Ming-Sound Tsao, Karl-Otto Kambartel, Hiroshi Isobe, Ming-Shyan Huang, Carlos H. Barrios, Adnan Khattak, Filippo de Marinis, Smita Kothari, Ashwini Arunachalam, Xiting Cao, Thomas Burke, Amparo Valladares, Javier de Castro, Aamir Ahmad
    PLOS ONE.2018; 13(8): e0202865.     CrossRef
  • Microfluidics-based immunofluorescence for fast staining of ALK in lung adenocarcinoma
    Saška Brajkovic, Benjamin Pelz, Maria-Giuseppina Procopio, Anne-Laure Leblond, Grégoire Repond, Ariane Schaub-Clerigué, Diego G Dupouy, Alex Soltermann
    Diagnostic Pathology.2018;[Epub]     CrossRef
  • Expanded Circulating Tumor Cells from a Patient with ALK- Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study
    Zhuo Zhang, Hiroe Shiratsuchi, Nallasivam Palanisamy, Sunitha Nagrath, Nithya Ramnath
    Journal of Thoracic Oncology.2017; 12(2): 397.     CrossRef
  • Molecular Testing of Lung Cancers
    Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
    Journal of Pathology and Translational Medicine.2017; 51(3): 242.     CrossRef
  • Novel ALK fusion partners in lung cancer
    Aglaya G. Iyevleva, Grigory A. Raskin, Vladislav I. Tiurin, Anna P. Sokolenko, Natalia V. Mitiushkina, Svetlana N. Aleksakhina, Aigul R. Garifullina, Tatiana N. Strelkova, Valery O. Merkulov, Alexandr O. Ivantsov, Ekatherina Sh. Kuligina, Kazimir M. Pozha
    Cancer Letters.2015; 362(1): 116.     CrossRef
  • Strategic management of transthoracic needle aspirates for histological subtyping and EGFR testing in patients with peripheral lung cancer: An institutional experience
    Choonhee Son, Eun‐Ju Kang, Mee Sook Roh
    Diagnostic Cytopathology.2015; 43(7): 532.     CrossRef
  • Current and future molecular diagnostics in non-small-cell lung cancer
    Chun Man Li, Wing Ying Chu, Di Lun Wong, Hin Fung Tsang, Nancy Bo Yin Tsui, Charles Ming Lok Chan, Vivian Wei Wen Xue, Parco Ming Fai Siu, Benjamin Yat Ming Yung, Lawrence Wing Chi Chan, Sze Chuen Cesar Wong
    Expert Review of Molecular Diagnostics.2015; 15(8): 1061.     CrossRef
  • Role of biopsy sampling for diagnosis of early and progressed hepatocellular carcinoma
    Haeryoung Kim, Young Nyun Park
    Best Practice & Research Clinical Gastroenterology.2014; 28(5): 813.     CrossRef
  • Molecular Pathology of Lung Cancer: Current Status and Future Directions
    Mee Sook Roh
    Tuberculosis and Respiratory Diseases.2014; 77(2): 49.     CrossRef
  • Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity
    Sung-Jun Ko, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Jin-Haeng Chung, Tae Jung Kim, Kyung Won Lee, Kwhanmien Kim, Sanghoon Jheon, Hyojin Kim, Jae Ho Lee, Choon-Taek Lee
    BMC Cancer.2014;[Epub]     CrossRef
Original Articles
Cytological Findings of the Micropapillary Variant of Urothelial Carcinoma: A Comparison with Typical High-Grade Urothelial Carcinoma
Kyu-Ho Kim, Chang-Hwan Choi, Jee-Young Han, Lucia Kim, Suk-Jin Choi, In-Suh Park, Joon-Mee Kim, Young-Chae Chu
Korean J Pathol. 2013;47(4):365-371.   Published online August 26, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.4.365
  • 5,964 View
  • 40 Download
  • 4 Crossref
AbstractAbstract PDF
Background

Micropapillary variant of urothelial carcinoma (MPUC) showed distinct pathologic features and aggressive behavior. The cytologic findings of MPUC are still indistinct. In this study, we evaluated the cytological findings of MPUC compared with those of high-grade urothelial carcinoma (HGUC).

Methods

The voided urine cytology of 8 cases of MPUC and 8 cases of HGUC was reviewed. Following cytological parameters were evaluated: cellularity, background, number of small, tight papillary clusters, small acinar structure, scattered single cells, cytoplasmic features, nuclear-to-cytoplasmic ratio, nuclear pleomorphism, nuclear membrane irregularity, hyperchromasia, chromatin pattern and nucleoli.

Results

Compared to that of HGUC, cytology of MPUC showed large numbers of small, tight papillary clusters, small acinar structure, few numbers of single cells, and hyperchromatic nuclei. Other parameters were similar between the two groups; both groups showed similar cellularity, dense or vacuolated cytoplasm, moderate to severe nuclear pleomorphism, irregular nuclear membrane, coarse granular chromatin, and small and prominent nucleoli.

Conclusions

The urine cytology of MPUCs showed smaller and tighter papillary cell clusters, more small acinar structures, fewer numbers of scattered single cells, and more hyperchromatic nuclei than that of HGUC. These features can help to distinguish MPUC and HGUC and offer an early cytological diagnosis of MPUC.

Citations

Citations to this article as recorded by  
  • Cytologic features of micropapillary variant urothelial carcinoma in urinary tract cytology: Case series and review of literature
    Nancy Y. Greenland, Yue Peng, Poonam Vohra, Z. Laura Tabatabai
    Diagnostic Cytopathology.2022;[Epub]     CrossRef
  • Cyto-histo correlations of plasmacytoid and micropapillary variants of high-grade urothelial carcinoma: do they fit well in The Paris System for reporting urinary cytology?
    Liye Suo, Ivonne Vega, Michael Thrall
    Journal of the American Society of Cytopathology.2021; 10(1): 20.     CrossRef
  • A case report of urothelial carcinoma with combined micropapillary and plasmacytoid morphology in the urinary bladder
    Sanghui Park, Min‐Sun Cho, Kwang Hyun Kim
    Diagnostic Cytopathology.2016; 44(2): 124.     CrossRef
  • Two cases with the micropapillary variant of urothelial carcinoma of the urinary bladder
    Akiko KAGOTANI, Mitsuaki ISHIDA, Muneo IWAI, Nozomi IWAMOTO, Nozomi KASUGA, Yuji HAYASHI, Yoshimitsu MIYAHIRA, Ryoji KUSHIMA
    The Journal of the Japanese Society of Clinical Cytology.2016; 55(3): 165.     CrossRef
In-house Manual Construction of High-Density and High-Quality Tissue Microarrays by Using Homemade Recipient Agarose-Paraffin Blocks
Kyu Ho Kim, Suk Jin Choi, Yeon Il Choi, Lucia Kim, In Suh Park, Jee Young Han, Joon Mee Kim, Young Chae Chu
Korean J Pathol. 2013;47(3):238-244.   Published online June 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.3.238
  • 8,672 View
  • 75 Download
  • 6 Crossref
AbstractAbstract PDF
Background

Self-made tissue punches can be effectively used to punch holes in blank recipient paraffin blocks and extract tissue cores from the donor paraffin blocks for the low-cost construction of tissue microarrays (TMAs). However, variable degrees of section distortion and loss of the tissue cores can occurs during cutting of the TMAs, posing technical problems for in-house manual construction of high-density TMAs. We aimed to update the method for in-house manual TMA construction to improve the quality of high-density TMAs.

Methods

Blocks of agarose gel were subjected to the standard tissue processing and embedding procedure to prepare recipient agarose-paraffin blocks. The self-made tissue punches and recipient agarose-paraffin blocks were used to construct TMAs, which were completely melted and re-embedded in paraffin to make finished TMA blocks.

Results

The donor tissue cores were completely integrated into the surrounding paraffin of the recipient blocks. This method enabled us to construct high-density TMAs with significantly less section distortion or loss of tissue cores during microtomy.

Conclusions

Simple and inexpensive construction of high-density and high-quality TMAs can be warranted by using paraffinized agarose gels as recipient blocks.

Citations

Citations to this article as recorded by  
  • An introduction of an easy-operating and economical technique for tissue microarray preparation
    Yi-Jing Chen, Chun-Mei Yang, Jiang-Sheng Huang, Ping Wang, Yan-Hua Lv, Cheng Tang, Wei Deng
    Journal of Clinical Pathology.2020; 73(7): 403.     CrossRef
  • Optimization of Tissue Microarrays from Banked Human Formalin-Fixed Paraffin Embedded Tissues in the Cancer Research Setting
    Tammy Sexton, Gregory L. Kucera, Edward A. Levine, Kounosuke Watabe, Stacey S. O'Neill
    Biopreservation and Biobanking.2019; 17(5): 452.     CrossRef
  • Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis
    Yan-Wei Cao, Yong Liu, Zhen Dong, Lei Guo, En-Hao Kang, Yong-Hua Wang, Wei Zhang, Hai-Tao Niu
    Urologic Oncology: Seminars and Original Investigations.2018; 36(6): 311.e15.     CrossRef
  • Platelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis
    Jung-Hwan Yu, Joon Mee Kim, Ja Kyung Kim, Suk Jin Choi, Kwan Sik Lee, Jin-Woo Lee, Hye Young Chang, Jung Il Lee
    Oncotarget.2017; 8(24): 39534.     CrossRef
  • Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma
    Chang Hwan Choi, Young Hoon Park, Joo Han Lim, Suk Jin Choi, Lucia Kim, In Suh Park, Jee Young Han, Joon Mee Kim, Young Chae Chu
    Journal of Pathology and Translational Medicine.2016; 50(2): 96.     CrossRef
  • High Quality Tissue Miniarray Technique Using a Conventional TV/Radio Telescopic Antenna
    Mohamed A. Elkablawy, Abdulkader M. Albasri
    Asian Pacific Journal of Cancer Prevention.2015; 16(3): 1129.     CrossRef
No Detection of Simian Virus 40 in Malignant Mesothelioma in Korea
Minseob Eom, Jamshid Abdul-Ghafar, Sun-Mi Park, Joung Ho Han, Soon Won Hong, Kun Young Kwon, Eun Suk Ko, Lucia Kim, Wan Seop Kim, Seung Yeon Ha, Kyo Young Lee, Chang Hun Lee, Hye Kyoung Yoon, Yoo Duk Choi, Myoung Ja Chung, Soon-Hee Jung
Korean J Pathol. 2013;47(2):124-129.   Published online April 24, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.124
  • 8,129 View
  • 50 Download
  • 5 Crossref
AbstractAbstract PDF
Background

Simian virus 40 (SV40), a polyomavirus, was discovered as a contaminant of a human polio vaccine in the 1960s. It is known that malignant mesothelioma (MM) is associated with SV40, and that the virus works as a cofactor to the carcinogenetic effects of asbestos. However, the reports about the correlation between SV40 and MM have not been consistent. The purpose of this study is to identify SV40 in MM tissue in Korea through detection of SV40 protein and DNA.

Methods

We analyzed 62 cases of available paraffin-blocks enrolled through the Korean Malignant Mesothelioma Surveillance System and performed immunohistochemistry for SV40 protein and real-time polymerase chain reaction (PCR) for SV40 DNA.

Results

Of 62 total cases, 40 had disease involving the pleura (64.5%), and 29 (46.8%) were found to be of the epithelioid subtype. Immunostaining demonstrated that all examined tissues were negative for SV40 protein. Sufficient DNA was extracted for real-time PCR analysis from 36 cases. Quantitative PCR of these samples showed no increase in SV40 transcript compared to the negative controls.

Conclusions

SV40 is not associated with the development of MM in Korea.

Citations

Citations to this article as recorded by  
  • Binding of SV40’s Viral Capsid Protein VP1 to Its Glycosphingolipid Receptor GM1 Induces Negative Membrane Curvature: A Molecular Dynamics Study
    Raisa Kociurzynski, Sophie D. Beck, Jean-Baptiste Bouhon, Winfried Römer, Volker Knecht
    Langmuir.2019; 35(9): 3534.     CrossRef
  • Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033
    Kyeong Min Kwak, Domyung Paek, Seung-sik Hwang, Young-Su Ju, Mark Allen Pershouse
    PLOS ONE.2017; 12(8): e0183404.     CrossRef
  • The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms
    Leonardo Vinícius Monteiro de Assis, Mauro César Isoldi
    Tumor Biology.2014; 35(2): 889.     CrossRef
  • The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma
    Leonardo Vinícius Monteiro de Assis, Jamille Locatelli, Mauro César Isoldi
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2014; 1845(2): 232.     CrossRef
  • Pleural Mesothelioma: An Institutional Experience of 66 Cases
    Soomin Ahn, In Ho Choi, Joungho Han, Jhingook Kim, Myung-Ju Ahn
    Korean Journal of Pathology.2014; 48(2): 91.     CrossRef
Review & Perspective
Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group
Hyo Sup Shim, Jin-Haeng Chung, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Geon Kook Lee, Soon-Hee Jung, Se Jin Jang
Korean J Pathol. 2013;47(2):100-106.   Published online April 24, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.100
  • 9,298 View
  • 64 Download
  • 11 Crossref
AbstractAbstract PDF

Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

Citations

Citations to this article as recorded by  
  • Favorable Conditions for the Detection of EGFR T790M Mutation Using Plasma Sample in Patients with Non-Small-Cell Lung Cancer
    Insu Kim, Hee Yun Seol, Soo Han Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop Eom
    Cancers.2023; 15(5): 1445.     CrossRef
  • Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer
    Dorine de Jong, Jeeban P. Das, Hong Ma, Jacienta Pailey Valiplackal, Conor Prendergast, Tina Roa, Brian Braumuller, Aileen Deng, Laurent Dercle, Randy Yeh, Mary M. Salvatore, Kathleen M. Capaccione
    Cancers.2023; 15(10): 2855.     CrossRef
  • Coordination games in cancer
    Péter Bayer, Robert A. Gatenby, Patricia H. McDonald, Derek R. Duckett, Kateřina Staňková, Joel S. Brown, Jun Tanimoto
    PLOS ONE.2022; 17(1): e0261578.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy
    Justin J Kuhlman, Muhamad Alhaj Moustafa, Liuyan Jiang, Han W Tun
    Journal of Blood Medicine.2021; Volume 12: 833.     CrossRef
  • Molecular Testing of Lung Cancers
    Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
    Journal of Pathology and Translational Medicine.2017; 51(3): 242.     CrossRef
  • Strategic management of transthoracic needle aspirates for histological subtyping and EGFR testing in patients with peripheral lung cancer: An institutional experience
    Choonhee Son, Eun‐Ju Kang, Mee Sook Roh
    Diagnostic Cytopathology.2015; 43(7): 532.     CrossRef
  • Ultrasonography-Guided Core Biopsy of Supraclavicular Lymph Nodes for Diagnosis of Metastasis and Identification of Epidermal Growth Factor Receptor (EGFR) Mutation in Advanced Lung Cancer
    Jooae Choe, Mi Young Kim, Jung Hwan Baek, Chang-Min Choi, Hwa Jung Kim
    Medicine.2015; 94(29): e1209.     CrossRef
  • Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non‐small‐cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage
    Tae‐Jung Kim, Chan Kwon Park, Chang Dong Yeo, Kihoon Park, Chin Kook Rhee, Jusang Kim, Seung Joon Kim, Sang Haak Lee, Kyo‐Young Lee, Hyoung‐Kyu Yoon
    Journal of Surgical Oncology.2014; 110(3): 245.     CrossRef
  • Novel EGFR mutation-specific antibodies for lung adenocarcinoma: Highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry
    An Na Seo, Tae-In Park, Yan Jin, Ping-Li Sun, Hyojin Kim, Hyun Chang, Jin-Haeng Chung
    Lung Cancer.2014; 83(3): 316.     CrossRef
  • Molecular Pathology of Lung Cancer: Current Status and Future Directions
    Mee Sook Roh
    Tuberculosis and Respiratory Diseases.2014; 77(2): 49.     CrossRef
Case Study
Peripheral Primitive Neuroectodermal Tumor with Osseous Component of the Small Bowel Mesentery: A Case Study
Joon Mee Kim, Young Chae Chu, Chang Hwan Choi, Lucia Kim, Suk Jin Choi, In Suh Park, Jee Young Han, Kyung Rae Kim, Yoon-La Choi, Taeeun Kim
Korean J Pathol. 2013;47(1):77-81.   Published online February 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.1.77
  • 8,883 View
  • 45 Download
  • 6 Crossref
AbstractAbstract PDF

A case of peripheral primitive neuroectodermal tumor of the small bowel mesentery with osseous component is reported. A 23-year-old man was admitted to our hospital because of acute severe abdominal pain. Abdominal computed tomography revealed a large solid and cystic, oval shaped mass, measuring 11.0×6.0 cm in the pelvic cavity. Histologically the resected lesion consisted of sheets of undifferentiated small round cells forming Homer-Wright rosettes and perivascular pseudorosettes, and showed areas of osteoid and bone formation. Immunohistochemical studies revealed that tumor cells expressed positivity against CD99 (MIC2), CD57, neuron-specific enolase, and vimentin. Fluorescence in situ hybridization study revealed Ewing sarcoma breakpoint region 1 (EWSR1) gene rearrangement on chromosome 22q12. To the authors' knowledge this is the first documentation of a peripheral neuroectodermal tumor with osteoid and bone formation of the small bowel mesentery.

Citations

Citations to this article as recorded by  
  • Primary Ewing’s sarcoma in a small intestine – a case report and review of the literature
    Andrej Kolosov, Audrius Dulskas, Kastytis Pauza, Veslava Selichova, Dmitrij Seinin, Eugenijus Stratilatovas
    BMC Surgery.2020;[Epub]     CrossRef
  • Case report and literature review of Ewing's sarcoma in the gastrointestinal tract
    Christopher Bong, Iain Thomson, Guy Lampe
    Surgical Practice.2018; 22(2): 84.     CrossRef
  • Pediatric Ewing’s Sarcoma/Primitive Neuroectodermal Tumor (ES/PNET) Developed in the Small Intestine: A Case Report
    You Sun Kim, Hye Min Moon, Kyu Sang Lee, Young Suk Park, Hyun-Young Kim, Ji Young Kim, Jin Min Cho, Hyoung Soo Choi
    Clinical Pediatric Hematology-Oncology.2017; 24(2): 162.     CrossRef
  • Huge peripheral primitive neuroectodermal tumor of the small bowel mesentery at nonage: A case report and review of the literature
    Zhe Liu, Yuan-Hong Xu, Chun-Lin Ge, Jin Long, Rui-Xia Du, Ke-Jian Guo
    World Journal of Clinical Cases.2016; 4(9): 306.     CrossRef
  • Primary primitive neuroectodermal tumor arising in the mesentery and ileocecum: A report of three cases and review of the literature
    LIBO PENG, LIMIN YANG, NAN WU, BO WU
    Experimental and Therapeutic Medicine.2015; 9(4): 1299.     CrossRef
  • Une curieuse tumeur digestive à cellules rondes
    Alia Zehani, Ines Chelly, Beya Chelly, Jean-Michel Coindre, Slim Haouet, Nidhameddine Kchir
    Annales de Pathologie.2014; 34(2): 104.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine